Galapagos NV has entered into a binding framework agreement with Gilead Sciences to collaborate on developing gamgertamig, a clinical-stage BCMA×CD3 T cell engager for autoimmune diseases. Under the deal, Galapagos will receive 50% of Gilead's $1.675 billion upfront payment for acquiring Ouro Medicines plus 50% of contingent milestone payments. Galapagos will retain $500 million in cash for independent strategic initiatives and is eligible for up to $100 million in additional milestone payments, with tiered royalties of 20-23% on net sales.

Gilead Sciences agreed to acquire Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestone payments to strengthen its inflammation and autoimmune disease pipeline. The clinical-stage drug OM336, a bispecific T cell engager, will be co-developed with Galapagos NV, which will fund 50% of upfront costs and development expenses through registrational studies. Gilead retains global commercialization rights and will pay Galapagos 20-23% royalties on net sales.

Galapagos and Gilead are in advanced discussions for a strategic partnership following Gilead's acquisition of Ouro Medicines. Under the proposed collaboration, Galapagos would co-develop OM336 (gamgertamig), a BCMA-targeted T-cell engager for autoimmune diseases, with improved financial terms including 50% cost-sharing for registration studies and 20-23% royalties on net sales. The deal would also free up €500 million of Galapagos' capital for strategic flexibility.

Galapagos and Gilead are in advanced partnership discussions following Gilead's acquisition of Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestone payments. Under the proposed collaboration, Galapagos would pay 50% of acquisition costs, absorb Ouro's operating assets, and lead development through registrational studies, while Gilead retains commercialization rights and pays 20-23% royalties. The partnership would free up $500 million of Galapagos' cash for independent strategic initiatives.

U.S. stock futures were mixed on Tuesday following Monday's rally that saw the Dow Jones jump nearly 600 points to an all-time high, driven by geopolitical developments in Venezuela. Key movers include CoreWeave rising on Nvidia partnership plans, Vistra gaining on a $4.7 billion acquisition, and Microchip Technology advancing on better-than-expected guidance. Treasury yields held steady at 4.17% for the 10-year bond, with markets pricing in an 83.9% probability of unchanged Fed rates in January.

Galapagos NV reported promising Phase 2 results for GLPG5101, a CAR T-cell therapy for mantle cell lymphoma, showing 100% objective response rate and 96% complete response rate with minimal toxicity. However, the company intends to wind down its cell therapy activities.

Galapagos reported promising phase 2 results for GLPG5101, a CAR T-cell therapy for mantle cell lymphoma, showing 100% objective response rate and 96% complete response rate. The company simultaneously announced its intention to wind down cell therapy activities.

Bank of America Corporation crossed and then fell below the 5% voting rights threshold for Galapagos NV on November 12 and 14, 2025, respectively, following acquisition and disposal of voting rights and financial instruments.

Bank of America Corporation filed transparency declarations with Galapagos NV, indicating they crossed and then receded below the 5% voting rights threshold on November 12 and 14, 2025, respectively.

Galapagos NV plans to gradually discontinue its cell therapy activities after a strategic evaluation, aiming to improve operational efficiency and pursue new business development opportunities. The decision may impact approximately 365 employees across Europe, US, and China.

Galapagos NV plans to wind down its cell therapy business after a strategic review found no viable proposals for the business. The company intends to reallocate resources towards pursuing transformative business development opportunities, potentially impacting approximately 365 employees across multiple global sites.

Galapagos NV announced the appointment of Aaron Cox as their new Chief Financial Officer, effective July 7, 2025. Cox brings over two decades of leadership experience in the biotechnology and capital markets sectors, having previously served as Executive Vice President and CFO at Horizon Therapeutics.